Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription treatments. Always consult a qualified healthcare professional before starting, stopping, or modifying any medication or exercise programme.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have reshaped the treatment landscape for obesity. Clinical trial participants routinely lose 10–20% of body weight — figures that once required bariatric surgery. But a number buried inside those headline results deserves far more attention: a substantial portion of that weight is not fat.
It is muscle.
Losing muscle while losing weight is not a cosmetic inconvenience. Skeletal muscle is the body's primary site of glucose disposal, a major determinant of resting metabolic rate, and the tissue that keeps you functional as you age. When it disappears faster than fat, you end up lighter on the scale but metabolically compromised — more vulnerable to weight regain, insulin resistance, and long-term frailty. Understanding why GLP-1 medications accelerate muscle loss, and what you can do about it, is arguably more important than understanding how they suppress appetite.
The STEP trials — the landmark clinical programme behind Wegovy's approval — are the most comprehensive source of semaglutide efficacy data available. Subgroup analyses of body composition data from these trials found that approximately 39% of total weight loss was lean mass in some cohorts. That figure varies by baseline characteristics, activity level, and protein intake, but even conservative estimates place lean mass loss in the 25–35% range for most users who do not intervene.
To understand why this matters metabolically, consider what lean mass does for your energy balance. Each kilogram of skeletal muscle burns roughly 10 kcal per day at rest — modest individually, but significant across the body as a whole. A person who loses 5 kg of lean mass in the process of losing 15 kg total has reduced their resting metabolic rate by approximately 50 kcal per day. That sounds minor until you consider that weight maintenance requires hitting a precise caloric target every single day for the rest of your life. A lower target means less room for error and a faster slide back toward weight gain once medication is discontinued.
This dynamic is central to the weight regain pattern seen after GLP-1 cessation. Post-STEP trial follow-up data showed that the majority of lost weight was regained within two years of stopping semaglutide. Part of this reflects the return of appetite-regulating hormones to pre-treatment levels. But part of it is structural: patients have a lower resting metabolic rate than before they started, because they lost muscle alongside fat.
The most concerning outcome is what researchers call sarcopenic obesity — a condition in which body fat percentage remains high while lean mass is low. This phenotype carries worse metabolic consequences than simple overweight. It is associated with higher rates of type 2 diabetes, cardiovascular disease, and functional decline. GLP-1 medications, used without a muscle-preservation strategy, can inadvertently move people toward this phenotype even as the scale reads lower.
GLP-1 receptor agonists do not directly instruct the body to break down muscle. The lean mass loss is driven by a predictable set of downstream consequences of how the drugs work.
The most significant factor is the depth of the caloric deficit. GLP-1s suppress appetite powerfully — particularly in the early titration phase. Many users spontaneously reduce their caloric intake by 500–1,000 kcal per day, which is an aggressive deficit by any clinical standard. In a caloric deficit of this magnitude, the body increasingly relies on amino acids from muscle protein to meet energy demands, particularly if dietary protein is insufficient.
Reduced food intake compounds the problem at the level of protein availability. If someone was previously eating 2,200 kcal and is now eating 1,400 kcal, their protein intake has likely dropped proportionally unless they make a deliberate effort to front-load protein in their smaller meals. Most people do not make this adjustment instinctively.
The third factor is reduced physical activity. Nausea, fatigue, and gastrointestinal discomfort — especially during dose escalation — reduce the practical capacity for exercise. Users who were walking 8,000 steps per day may drop to 4,000. Those who trained at the gym regularly may skip sessions for weeks at a time. The result is a prolonged period where muscle protein synthesis signals are absent while the catabolic pressure of a deep caloric deficit continues.
Finally, GLP-1 receptor agonists have no direct anabolic or muscle-preserving mechanism. They reduce appetite and slow gastric emptying — both highly effective for fat loss — but they do not upregulate muscle protein synthesis, increase anabolic hormone activity, or preferentially spare lean mass. What protection muscle receives must come entirely from external inputs: diet, exercise, and supplementation.
The most powerful intervention for preserving lean mass during GLP-1 therapy is resistance training. This is not a soft recommendation — it is the gold-standard, evidence-based prescription backed by a mechanistically sound explanation.
Resistance exercise triggers muscle protein synthesis through pathways (mTOR, mechano-growth factor, satellite cell activation) that operate independently of caloric status. Even in a significant caloric deficit, a muscle that has been subjected to progressive mechanical load will receive an anabolic signal that partially offsets the catabolic pressure of reduced energy intake. This is why DEXA scan data from trials pairing resistance training with GLP-1 therapy consistently show significantly better lean mass preservation than medication alone.
A practical minimum is 2–3 full-body resistance training sessions per week. The sessions do not need to be lengthy, but they must include compound movements that recruit large amounts of muscle mass simultaneously:
The progressive overload principle is non-negotiable. Muscles adapt to the specific demand placed on them — if the load does not increase over time, the stimulus becomes insufficient to drive or even maintain muscle mass. This means tracking weights and aiming to add load or reps across sessions, even modestly.
Walking — while valuable for cardiovascular health and general activity — does not provide the mechanical stimulus required to preserve or build skeletal muscle. It is a complement to resistance training, not a substitute.
For users experiencing significant GLP-1-related fatigue, shorter sessions (30–40 minutes) at a controlled intensity are more sustainable than infrequent, exhausting workouts. Consistency over months matters more than intensity on any given day.
Dietary protein is the substrate from which muscle is built and maintained. During GLP-1 therapy, the standard population guideline of 0.8 g/kg body weight — set for sedentary adults to prevent deficiency, not for people in an active caloric deficit — is wholly inadequate.
For GLP-1 users engaged in resistance training, the evidence-supported target is 1.6–2.2 g of protein per kilogram of ideal body weight per day. The use of ideal body weight rather than current weight is intentional: if someone is significantly above their ideal weight, calculating protein from their current mass would produce an unnecessarily high and impractical target. Ideal body weight provides a more clinically appropriate anchor.
Distribution across the day matters as much as total intake. Muscle protein synthesis responds to individual doses of leucine — an essential amino acid that acts as the primary anabolic trigger. A threshold of approximately 2.5 g of leucine per meal is required to maximally stimulate muscle protein synthesis; below this threshold, the anabolic response is blunted. In practice, this means consuming at least 25–40 g of high-quality protein per meal, spread across 3–4 eating occasions.
High-quality protein sources include:
The practical challenge for GLP-1 users is that smaller meal volumes make hitting protein targets difficult. The strategic solution is to prioritise protein before all other macronutrients within each meal. Eat the protein first. If satiety sets in before finishing the meal, the protein has been consumed and carbohydrates or fats can be reduced without compromising lean mass preservation.
Protein shakes are a particularly useful tool in this context — they deliver 25–40 g of protein in a low-volume, easily tolerated format on days when solid food is unappealing due to GLP-1-related nausea.
Among the supplements with genuine evidence behind them, creatine monohydrate stands out as particularly relevant for GLP-1 users.
Creatine is a naturally occurring compound stored primarily in skeletal muscle as phosphocreatine. It functions as a rapid resynthesis substrate for ATP during high-intensity muscle contractions — meaning it directly supports the kind of work resistance training demands. Higher creatine stores translate to better training performance at a given level of fatigue, which is especially relevant for users whose training capacity is compromised by GLP-1-related tiredness.
A 2022 Cochrane review examining creatine supplementation in combination with resistance training found consistent evidence that creatine plus resistance training outperforms resistance training alone for lean mass outcomes. The effect is modest but reliable, and it stacks additively with the benefits of training itself.
The practical protocol is straightforward: 3–5 g of creatine monohydrate per day, taken consistently. A loading phase (20 g/day for 5–7 days) accelerates saturation of muscle stores but is not necessary — a standard maintenance dose reaches the same endpoint within 3–4 weeks. Creatine monohydrate is the most studied form; there is no credible evidence that more expensive formulations (creatine HCl, buffered creatine) are superior.
Beyond the established protocol of training, protein, and creatine, researchers are actively investigating whether other compounds can further reduce lean mass loss during aggressive caloric restriction. Peptide research on muscle preservation is one area attracting increasing scientific attention, with mechanistic work exploring how specific signalling peptides interact with muscle protein turnover pathways during negative energy balance. While this research is preliminary and not yet at the stage of clinical recommendations, it represents an active frontier in the optimisation of body composition outcomes during pharmaceutical weight loss.
For a broader discussion of how these principles apply across different medications, see our GLP-1 medication comparison.
Weight on a scale is a poor proxy for the quality of weight loss. A person losing weight rapidly could be shedding mostly fat — an excellent outcome — or mostly muscle — a metabolic problem in the making. Without body composition measurement, it is impossible to distinguish between the two.
The gold standard for body composition assessment is a DEXA (dual-energy X-ray absorptiometry) scan, which provides precise measurements of fat mass, lean mass, and bone density. InBody bioimpedance devices are a more accessible alternative available at many gyms and clinics; while less precise than DEXA, they are sufficient for tracking directional trends.
A sensible monitoring protocol for GLP-1 users:
If scans reveal that lean mass is declining faster than this threshold, the protocol needs immediate adjustment — typically increasing protein intake, adding or intensifying resistance training, or both.
Translating targets into daily eating requires a practical structure. For users navigating reduced appetite on GLP-1s, the priority hierarchy for meal construction is:
A sample high-protein day on a reduced calorie intake might look like:
This structure can deliver 140–160 g of protein across moderate meal volumes — achievable even for users with significantly suppressed appetite.
For principles that extend beyond medication-assisted weight loss, the science of body recomposition principles provides a useful foundation for understanding how muscle and fat tissue respond to combined dietary and training interventions.
GLP-1 medications are effective tools for reducing body weight, but "weight loss" and "fat loss" are not synonymous. The evidence from the STEP trials and subsequent body composition analyses is unambiguous: without deliberate muscle-preservation strategies, a significant proportion of the weight lost will come from lean mass — reducing metabolic rate, increasing rebound risk, and potentially worsening long-term metabolic health.
The protocol to address this is not complicated, but it requires consistency:
For men in the later stages of life where muscle loss and metabolic slowdown are compounding factors, these principles are particularly important; see our detailed discussion of weight loss strategies for men over 50 for age-specific adaptations to this protocol.
GLP-1 medications can be transformative. The goal of this protocol is to ensure that transformation is predominantly fat loss — and that the metabolic infrastructure to sustain it remains intact.
A research overview of how recombinant HGH (somatropin) activates the growth hormone receptor and JAK2/STAT5 signalling to drive hepatic IGF-1 production.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.